Skip to main content
SpringerLink
Log in

Antiviral Chemotherapy for Viral Hepatitis

  • Chapter
Book cover Viral Hepatitis

  • 178 Accesses

Abstract

Chronic hepatitis B viral infection remains one of the major medical problems in the world and is a leading cause of morbidity and mortality. Advances in the treatment and prevention of hepatitis B virus (HBV) infection represent among the most dramatic achievements of modern medicine and have resulted from fully exploiting discoveries in molecular immunology and virology as well as rational drug design. The first major breakthrough in the therapy of HBV was the development of regimens of interferon-alfa that give 30–40% long term remission rates in chronically infected patients. Despite this advance, the glass has also remained half empty. The more recent development of nucleoside analog agents with potent antiviral activity have now provided additional armamentarium in the care of HBV infected patients. The initial part of this chapter will address, in a practical manner, the therapy of appropriate patients with interferon and the anticipated effects and benefits of this therapy. The chapter will then discuss the evolving role of nucleoside analogs and even more experimental agents in the management of patients who are either refractory to or are poor candidates for interferon-alfa therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Hoofnagle, J. H., Shafritz, D. A., and Popper, H. (1987) Chronic type B hepatitis and the “healthy” HBsAg carrier state (review). Hepatology 7 (4), 758–763.

    PubMed  CAS  Google Scholar 

  2. Perrillo, R. P. (1994) The management of chronic hepatitis B (review). Amer. J. Med. 96 (1A), 34S - 39S.

    PubMed  CAS  Google Scholar 

  3. Lohr, H. F., Weber, W., Schlaak, J., Goergen, B., Meyer zum Buschenfelde, K. H., and Gerken, G. (1995) Proliferative response of CD4+ T cells and hepatitis B virus clearance in chronic hepatitis with or without hepatitis B e-minus hepatitis B virus mutants. Hepatology 22 (1), 61–68.

    PubMed  CAS  Google Scholar 

  4. Rehermann, B., Lau, D., Hoofnagle, J. H., and Chisari, E. V. (1996) Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J. Clin. Invest. 97 (7), 1655–1665.

    PubMed  CAS  Google Scholar 

  5. Peters, M. (1989) Mechanisms of action of interferons (review). Sem. Liver Dis. 9 (4), 235–239.

    CAS  Google Scholar 

  6. Don, R. T. (1993) Interferon-alpha in malignant and viral diseases. A review. Drugs 45 (2), 177–211.

    Google Scholar 

  7. Grossberg, S. E., Taylor, J. L., and Kushnaryov, V. M. (1989) Interferon receptors and their role in interferon action (review). Experientia 45 (6), 508–513.

    PubMed  CAS  Google Scholar 

  8. Solinas, A., Cossu, P., Poddighe, P., Tocco, A., Deplano, A., Garrucciu, G., and Diana, M. S. (1993) Changes of serum 2’, 5’-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis C. Liver 13 (5), 253–258.

    PubMed  CAS  Google Scholar 

  9. Horisberger, M. A., Staeheli, P., and Haller, O. (1983) Interferon induces a unique protein in mouse cells bearing a gene for resistance to influenza virus. Proc.Natl. Acad. Sci. USA 80 (1), 1910–1914.

    PubMed  CAS  Google Scholar 

  10. Hoofnagle, J. H. (1994) Therapy of acute and chronic viral hepatitis (review). Adv. Int. Med. 39, 241–275.

    CAS  Google Scholar 

  11. Perrillo, R. P., Schiff, E. R., Davis, G. L., Bodenheimer, H. C., Jr., Lindsay, K., Payne, J., Dienstag, J. L., O’Brien, C., Tamburro, C., Jacobson, I. M., et al. (1990) A randomized, controlled trial of interferon alpha-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group (see comments). N. Engl. J. Med. 323 (5), 295–301.

    PubMed  CAS  Google Scholar 

  12. Furuta, M., Akashi, K., Nakamura, Y., Matsumoto, K., Yamaguchi, H., Takamatsu, S., and Shimizu, T. (1987) 2’, 5’-Oligoadenylate synthetase activity in peripheral blood lymphocytes as a clinical marker in interferon therapy for chronic hepatitis B. J. Interferon Res. 7(1) 111–119.

    PubMed  CAS  Google Scholar 

  13. Perez, V., Tanno, H., Villamil, F., and Fay, O. (1990) Recombinant interferon alpha-2b following prednisone withdrawal in the treatment of chronic type B hepatitis. J. Hepatol. 11 (Suppl. 1), S113 — S117.

    PubMed  Google Scholar 

  14. Renault, P. F. and Hoofnagle, J. H. (1989) Side effects of alpha interferon (review). Sem. Liver Dis. 9 (4), 273–277.

    CAS  Google Scholar 

  15. Renault, R. F., Hoofnagle, J. H., Park, Y., Mullen, K. D., Peters, M., Jones, D. B., Rustgi, V., Jones, E. A. (1987) Psychiatric complications of long-term interferon alfa therapy. Arch. Int. Med. 147 (9), 1577–1580.

    CAS  Google Scholar 

  16. McLaughlin, P., Talpaz, M., Quesada, J. R., Saleem, A., Barlogie, B., Gutterman, J. U. (1985) Immune thrombocytopenia following alpha-interferon therapy in patients with cancer. JAMA 254 (10), 1353–1354.

    PubMed  CAS  Google Scholar 

  17. Hoofnagle, J. H. (1991) Thrombocytopenia during interferon alfa therapy. JAMA 266 (6), 849.

    PubMed  CAS  Google Scholar 

  18. Vento, S., Di Perri, G., Garofano, T., Cosco, L., Concia, E., Ferraro, T., Bassetti, D. (1989) Hazards of interferon therapy for HBV-seronegative chronic hepatitis. Lancet 2(8668) 926.

    Google Scholar 

  19. Cianciara, J., Laskus, T. (1995) Development of transient autoimmune hepatitis during interferon treatment of chronic hepatitis B. Dig. Dis. Sci. 40 (8), 1842–1844.

    PubMed  CAS  Google Scholar 

  20. Mayet, W. J., Hess, G., Gerken, G., Rossol, S., Voth, R., Manns, M., and Meyer zum Buschenfelde, K. H. (1989) Treatment of chronic type B hepatitis with recombinant alpha-interferon induces autoantibodies not specific for autoimmune chronic hepatitis. Hepatology 10 (1), 24–28.

    PubMed  CAS  Google Scholar 

  21. Lisker-Melman, M., Di Bisceglie, A. M., Usala, S. J., Weintraub, B., Murray, L. M., Hoofnagle, J. H. (1992) Development of thyroid disease during therapy of chronic viral hepatitis. Gastroenterology 102 (6), 2155–2160.

    PubMed  CAS  Google Scholar 

  22. Waguri, M., Hanafusa, T., Itoh, N., Imagawa, A., Miyagawa, J., Kawata, S., Kono, N., Kuwajima, M., Matsuzawa, Y. (1994) Occurrence of IDDM during interferon therapy for chronic viral hepatitis. Diabetes Res. Clin. Practice 23 (1), 33–36.

    CAS  Google Scholar 

  23. Fabris, P., Betterle, C., Floreani, A., Greggio, N. A., de Lazzari, F., Naccarato, R., Chiaramonte, M. (1992) Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis. Lancet 340 (8818), 548.

    PubMed  CAS  Google Scholar 

  24. Lopes, E. P., Oliveira, P. M., Silva, A. E., Ferraz, M. L., Costa, C. H., Miranda, W., Dib, S. A. (1994) Exacerbation of type 2 diabetes mellitus during interferon-alfa therapy for chronic hepatitis B (letter). Lancet 343 (8891), 244.

    PubMed  CAS  Google Scholar 

  25. Fornaciari, G., Bassi, C., Beltrami, M., Castagnetti, E., Maccari, S., Plancher, A. C. (1991) Hemolytic anemia secondary to interferon treatment for chronic B hepatitis (letter). J. Clin. Gastroenterol. 13 (5), 596–597.

    PubMed  CAS  Google Scholar 

  26. Akard, L. P., Hoffman, R., Elias, L., Saiers, J. H. (1986) Alpha-interferon and immune hemolytic anemia (letter). Ann. Int. Med. 105 (2), 306.

    PubMed  CAS  Google Scholar 

  27. Yoshida, E. M., Rock, N. R., Zeng, L., Haniak, W. A., Anderson, F. H. (1995) The use of interferon-alpha 2B in the treatment of chronic viral hepatitis in patients with preexisting idiopathic thrombocytopenic purpura (letter; comment). Amer. J. Gastroenterol. 90 (5), 854–855.

    CAS  Google Scholar 

  28. Hayasaka, S., Fujii, M., Yamamoto, Y., Noda, S., Kurome, H., and Sasaki, M. (1995) Retinopathy and subconjunctival haemorrhage in patients with chronic viral hepatitis receiving interferon alfa. Br. J. Ophthalmol. 79 (2), 150–152.

    PubMed  CAS  Google Scholar 

  29. Miranda-Guardiola, F., Fernandez-Llama, P., Badia, J. R., Botey, A., Estruch, R., Darnell, A., Rozman, C., and Revert, L. (1995) Acute renal failure associated with alpha-interferon therapy for chronic hepatitis B. Nephrol. Dial. Transplant. 10 (8), 1441–1443.

    PubMed  CAS  Google Scholar 

  30. Kanda, Y., Shigeno, K., Kinoshita, N., Nakao, K., Yano, M., and Matsuo, H. (1994) Sudden hearing loss associated with interferon. Lancet 343 (8906), 1134–1135.

    PubMed  CAS  Google Scholar 

  31. Wong, D. K., Cheung, A. M., O’Rourke, K., Naylor, C. D., and Detsky, A. S. (1993) Effect of alpha-interferon treatment in patients with hepatitis B e. Ann. Int. Med. 119 (4), 312–323.

    PubMed  CAS  Google Scholar 

  32. Carreno, V., Castillo, I., Molina, J., Pones, J. C., and Bartolome (1992) Long-term follow-up of hepatitis B chronic carriers who responded to interferon therapy. J. Hepatol. 15 (1–2), 102–106.

    PubMed  CAS  Google Scholar 

  33. Niederau, C., Heintges, T., Lange, S., Goldmann, G., Niederau, C. M., Mohr, L., and Haussinger, D. (1996) Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B (see comments). N. Engl. J. Med. 334 (22), 1422–1427.

    PubMed  CAS  Google Scholar 

  34. Korenman, J., Baker, B., Waggoner, J., Everhart, J. E., Di Bisceglie, A. M., and Hoofnagle, J. H. (1991) Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann. Int. Med. 114 (8), 629–634.

    PubMed  CAS  Google Scholar 

  35. Hope, R. L., Weltman, M., Dingley, J., Fiatarone, J., Hope, A. H., Craig, P.I., Grierson, J. M., Bilous, M., Williams, S. J., and Farrell, G. C. (1995) Interferon alfa for chronic active hepatitis B. Long term follow-up of 62 patients: outcomes and predictors of response. Med. J. Australia 162 (1), 8–11.

    PubMed  CAS  Google Scholar 

  36. Fong, T. L., Di Bisceglie, A. M., Gerber, M. A., Waggoner, J. G, Hoofnagle, J. H. (1993) Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B. Hepatology 18 (6), 1313–1318.

    PubMed  CAS  Google Scholar 

  37. Perrillo, R. P. and Brunt, E. M. (1991) Hepatic histologic and immunohistochemical changes in chronic hepatitis B. Ann. Int. Med. 115 (2), 113–115.

    PubMed  CAS  Google Scholar 

  38. Krogsgaard, K., Bindslev, N., Christensen, E., Craxi, A., Schlichting, P., Schalm, S., Carreno, V., Trepo, C., Gerken, G., Thomas, H. C., et al. (1994) The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. European Concerted Action on Viral Hepatitis (Eurohep). J. Hepatol. 21 (4), 646–655.

    PubMed  CAS  Google Scholar 

  39. Lai, C. L., Lok, A. S., Lin, H. J., Wu, P. C., Yeoh, E. K., and Yeung, C. Y. (1987) Placebo-controlled trial of recombinant alpha 2-interferon in Chinese HBsAg-carrier children. Lancet 2 (8564), 877–880.

    PubMed  CAS  Google Scholar 

  40. Lok, A. S. (1993) Antiviral therapy of the Asian patient with chronic hepatitis B (review). Sem. Liver Dis. 13 (4), 360–366.

    CAS  Google Scholar 

  41. Perrillo, R. P. (1995) Chronic hepatitis B: problem patients (including patients with decompensated disease) (review). J. Hepatol. 22 (Suppl. 1), 45–48.

    PubMed  CAS  Google Scholar 

  42. Wright, H. I., Gavaler, J. S., and Van Thiel, D. H. (1992) Preliminary experience with alpha-2b-interferon therapy of viral hepatitis in liver allograft recipients. Transplantation 53, 121–124.

    PubMed  CAS  Google Scholar 

  43. Tur-Kaspa, R., Burk, R. D., Shaul, Y., Shafritz, D. A.. (1986) Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc. Natl. Acad. Sci. USA 83 (6), 1627–1631.

    PubMed  CAS  Google Scholar 

  44. Hirai, N., Shimizu, M., Morioka, T., Hinoue, Y., Tanaka, N., Kobayashi, K., Hattori, N., and Hashimoto, T. (1988) Activities of the interferon system in patients with HBsAg-positive chronic hepatitis B during short-term steroid withdrawal therapy. Liver 8 (3), 138–145.

    PubMed  CAS  Google Scholar 

  45. Niederau, C., Heintges, T., Niederau, M., Stremmel, W., and Strohmeyer, G. (1992) Prospective randomized controlled trial of sequential treatment with corticoids and alpha-interferon versus treatment with interferon alone in patients with chronic active hepatitis B. Eur. J. Med. 1 (7), 396–402.

    PubMed  CAS  Google Scholar 

  46. Cohard, M., Poynard, T., Mathurin, P., and Zarski, J. P. (1994) Prednisone-interferon combination in the treatment of chronic hepatitis B: direct and indirect metanalysis. Hepatology 20 (6), 1390–1398.

    PubMed  CAS  Google Scholar 

  47. Liaw, Y. F., Lin, S. M., Chen, T. J., Chien, R. N., Sheen, I. S., and Chu, C. M. (1994) Beneficial effect of prednisolone withdrawal followed by human lymphoblastoid interferon on the treatment of chronic type B hepatitis in Asians: a randomized controlled trial. J. Hepatol. 20 (2), 175–180.

    PubMed  CAS  Google Scholar 

  48. Perrillo, R. P., and Regenstein, F. G. (1986) Corticosteroid therapy for chronic active hepatitis B: is a little to much? Hepatology 6 (6), 1416–1418.

    PubMed  CAS  Google Scholar 

  49. Brunetto, M. R., Giarin, M., Oliveri, F., Saracco, G., and Barbera, C. (1991) “e” antigen defective hepatitis B virus and course of chronic infection. J. Hepatol. 13(Suppl. 4), S82–86.

    Google Scholar 

  50. Fattovich, G., Farci, P., Rugge, M., Brollo, L., Mandas, A., Pontisso, P., Giustina, G., Lai, M. E., Belussi, F., Busatto, G., et al. (1992) A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg. Hepatology 15 (4), 584–589.

    PubMed  CAS  Google Scholar 

  51. Andreone, P., Cursaro, C., Gramenzi, A., Zavaglio, C., Rezakovic, I., Altomare, E., Severini, R., Franzone, J. S., Albano, O., Ideo, G., Bernardi, M., and Gasbarrini, G. (1996) A randomized controlled trial of thymosin-al versus interferon alfa treatment in patients with hepatitis B e antigen antibody-and hepatitis B virus DNA-positive chronic hepatitis B. Hepatology 24, 774–777.

    PubMed  CAS  Google Scholar 

  52. Lok, A. S., Wu, P C., Lai, C. L., Lau, J. Y., Leung, E. K., Wong, L. S., Ma, O. C., Lauder, I. J., Ng, C. R, and Chung, H. T. (1992) A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 102 (6), 2091–2097.

    PubMed  CAS  Google Scholar 

  53. Lok, A. S., Chung, H. T., Liu, V. W., and Ma, O. C. (1993) Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 105 (6), 1833–1838.

    PubMed  CAS  Google Scholar 

  54. Tong, M. J., and Hwang, S. J. (1994) Hepatitis B virus infection in Asian Americans (review). Gastroenterol. Clin. N. Amer. 23 (3), 523–536.

    CAS  Google Scholar 

  55. Utili, R., Sagnelli, E., Gaeta, G. B., Galanti, B., Nardiello, S., Felaco, F. M., Pasquale, G., Marrone, A., Aprea, L., Pizzella, T., et al. (1994) Treatment of chronic hepatitis B in children with prednisone followed by alfa-interferon: a controlled randomized study. J. Hepatol. 20 (2), 163–167.

    PubMed  CAS  Google Scholar 

  56. Bruguera, M., Amat, L., Garcia, O., Lambruschini, N., Carnicer, J., Bergada, A., Martin Orte, E., Costa, J., Sanchez-Tapias, J. M., and Rodes, J. (1993) Treatment of chronic hepatitis B in children with recombinant alfa interferon. Different response according to age at infection. J. Clin. Gastroenterol. 17 (4), 296–299.

    PubMed  CAS  Google Scholar 

  57. Ruiz-Moreno, M., Camps, T., Jimenez, J., Lopez, R., Castillo, I., Bartolome, J., and Carreno, V. (1995) Factors predictive of response to interferon therapy in children with chronic hepatitis B. J. Hepatol. 22 (5), 540–544.

    PubMed  CAS  Google Scholar 

  58. Barbera, C., Bortolotti, F., Crivellaro, C., Coscia, A., Zancan, L., Cadrobbi, P., Nebbia, G., Pillan, M. N., Lepore, L., Parrella, T., et al. (1994) Recombinant interferon-alpha 2a hastens the rate of HBeAg clearance in children with chronic hepatitis B. Hepatology 20 (2), 287–290.

    PubMed  CAS  Google Scholar 

  59. Sokal, E. M., Wirth, S., Goyens, P., Depreterre, A., and Cornu, C. (1993) Interferon alpha-2b therapy in children with chronic hepatitis B. Gut 34 (2 Suppl), S87 - S90.

    Google Scholar 

  60. Cullu, F., Tumay, G. T., Kutlu, T., Erkan, T., Ozbay, G., and Badur, S. (1995) (Treatment of chronic viral hepatitis B in children with moderate doses of alpha interferon). (Review) (French). Gastroenterol. Clin. Biol. 19(1) 53–57.

    Google Scholar 

  61. Anonymous (1990) Protection against viral hepatitis. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 39 (RR-2), 1–26.

    Google Scholar 

  62. Stevens, C. E., Taylor, P. E., Tong, M. J., Toy, P. T., Vyas, G. N., and Nair (1987) Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission. JAMA 257 (19), 2612–2616.

    PubMed  CAS  Google Scholar 

  63. Wong, D. K., Yim, C., Naylor, C. D., Chen, E., Sherman, M., Vas, S., Wanless, I. R., Read, S., Li, H., and Heathcote, E. J. (1995) Interferon alfa treatment of chronic hepatitis B: randomized trial in a predominantly homosexual male population. Gastroenterology 108 (1), 165–171.

    PubMed  CAS  Google Scholar 

  64. Brook, M. G., McDonald, J.A., Karayiannis, P., Caruso, L., Forster, G., Harris, J. R., and Thomas, H. C. (1989) Randomised controlled trial of interferon alfa 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response. Gut 30 (8), 1116–1122.

    PubMed  CAS  Google Scholar 

  65. Hoofnagle, J. H., Peters, M., Mullen, K. D., Jones, D. B., Rustgi, V., Di Bisceglie, A., Hallahan, C., Park, Y., Meschievitz, C., and Jones, E. A. (1988) Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology 95 (5), 1318–1325.

    PubMed  CAS  Google Scholar 

  66. Hoofnagle, J. H., Di Bisceglie, A. M., Waggoner, J. G., and Park, Y. (1993) Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 104 (4), 1116–1121.

    PubMed  CAS  Google Scholar 

  67. Perrillo, R., Tamburro, C., Regenstein, F., Balart, L., Bodenheimer, H., Silva, M., Schiff, E., Bodicky, C., Miller, B., Denham, C., et al. (1995) Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 109 (3), 908–916.

    PubMed  CAS  Google Scholar 

  68. Nevens, F., Goubau, P., Van Eyken, P., Desmyter, J., Desmet, V., and Fevery, J. (1993) Treatment of decompensated viral hepatitis B-induced cirrhosis with low doses of interferon alpha. Liver 13 (1), 15–19.

    PubMed  CAS  Google Scholar 

  69. Di Bisceglie, A. M. (1995) Long-term outcome of interferon-alpha therapy for chronic hepatitis B (review). J. Hepatol. 22 (Suppl. 1), 65–67.

    PubMed  Google Scholar 

  70. Tassopoulos, N. C., Hadziyannis, S. J., and Wright, G. E. (1989) Recombinant human interferon alpha-2b in the management of acute type B hepatitis. Hepatology 10, 576A.

    Google Scholar 

  71. Sanchez-Tapias, J. M., Mas, A., and Costa, J. (1987) Recombinant alpha 2c-interferon therapy in fulminant viral hepatitis. J. Hepatol. 5 (2), 205–210.

    PubMed  CAS  Google Scholar 

  72. Liaw, Y. F. (1995) Role of hepatitis C virus in dual and triple hepatitis virus infection (review). Hepatology 22 (4 Pt. 1), 1101–1108.

    PubMed  CAS  Google Scholar 

  73. Weltman, M.D., Brotodihardjo, A., Crewe, E. B., Farrell, G. C., Bilous, M., Grierson, J. M., and Liddle, C. (1995) Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. J. Viral Hep. 2 (1), 39–45.

    CAS  Google Scholar 

  74. Poniachik, J., Reddy, R., Jeffers, L., and Bernstein, D., Jonnalagadda, S., De Medina, M., O’Sullivan, H., Li, X. M., and Schiff, E. R. (1995) Quantitative hepatitis B virus DNA and hepatitis C virus RNA levels in co-infected patients. Hepatology 22 (4 Part 2), 266.

    Google Scholar 

  75. Martin, P. (1994) Hepatitis C infection in patients with chronic hepatitis B: curiosity or cofactor? Amer. J. Gastroenterol. 89 (8), 1139–1141.

    CAS  Google Scholar 

  76. Lai, K. N., Li, P. K., Lui, S. F., Au, T. C., Tam, J. S., Tong, K. L., and Lai, F. M. (1991) Membranous nephropathy related to hepatitis B virus in adults. N. Engl. J. Med. 324 (21), 1457–1463.

    PubMed  CAS  Google Scholar 

  77. Conjeevaram, H. S., Hoofnagle, J. H., Austin, H. A., Park, Y., Fried, M. W., and Di Bisceglie, A. M. (1995) Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with interferon alfa. Gastroenterology 109 (2), 540–546.

    PubMed  CAS  Google Scholar 

  78. Lin, C. Y. (1995) Treatment of hepatitis B virus-associated membranous nephropathy with recombinant alpha-interferon. Kidney Intern. 47 (1), 225–230.

    CAS  Google Scholar 

  79. Scully, L. J., Karayiannis, R, and Thomas, H. C. (1992) Interferon therapy is effective in treatment of hepatitis B-induced polyarthritis. Dig. Dis. Sci. 37 (11), 1757–1760.

    PubMed  CAS  Google Scholar 

  80. Lohr, H., Goergen, B., Weber, W., Godderz, W., Meyer zum Buschenfelde, K. H., and Gerken, G. (1994) Mixed cryoglobulinemia type II in chronic hepatitis B associated with HBe-minus HBV mutant: cellular immune reactions and response to interferon treatment. J. Med. Virol. 44 (4), 330–335.

    PubMed  CAS  Google Scholar 

  81. Bonkovsky, H. L., Liang, T. J., Hasegawa, K., and Banner, B. (1995) Chronic leukocytoclastic vasculitis complicating HBV infection. Possible role of mutant forms of HBV in pathogenesis and persistence of disease. J. Clin. Gastroenterol. 21 (1), 42–47.

    PubMed  CAS  Google Scholar 

  82. Guillevin, L., Lhote, F., Leon, A., Fauvelle, F., Vivitski, L., and Trepo, C. (1993) Treatment of polyarteritis nodosa related to hepatitis B virus with short term steroid therapy associated with antiviral agents and plasma exchanges. A prospective trial in 33 patients. J. Rheumatol. 20 (2), 289–298.

    PubMed  CAS  Google Scholar 

  83. Mouthon, L., Deblois, R, Sauvaget, F., Meyrier, A., Callard, P., and Guillevin, L. (1995) Hepatitis B virus-related polyarteritis nodosa and membranous nephropathy. Amer. J. Nephrol. 15 (3), 266–269.

    CAS  Google Scholar 

  84. Wong, S. N., Yu, E. C., and Chan, K. W. (1993) Hepatitis B virus associated membranous glomerulonephritis in children—experience in Hong Kong. Clin. Nephrol. 40 (3), 142–147.

    PubMed  CAS  Google Scholar 

  85. Wong, J. B., Koff, R. S., Tine, F., and Pauker, S. G. (1995) Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. (See comments) Ann. Int. Med. 122 (9), 664–675.

    PubMed  CAS  Google Scholar 

  86. Dusheiko, G. M., and Roberts, J. A. (1995) Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal. (See comments) Hepatology 22 (6), 1863–1873.

    PubMed  CAS  Google Scholar 

  87. Koretz, R. L., and Ofman, J. (1996) Interferoning with natural history: dollars and sense. Gastroenterology 110 (1), 313–315.

    PubMed  CAS  Google Scholar 

  88. Koff, R. S., and Seeff, L. B. (1995) Economic modeling of treatment in chronic hepatitis B and chronic hepatitis C: promises and limitations. (Editorial; comment) Hepatology 22 (6), 1880–1882.

    PubMed  CAS  Google Scholar 

  89. Liao, M. J., Lee, N., Dipaola, M., Hussain, M., Brissette, R., Ni, D., Smith, T., Desai, M., Ferencz-Biro, K., and Testa, D. (1994) Distribution of interferon-alpha 2 genes in humans. J. Interferon Res. 14 (4), 183–185.

    PubMed  CAS  Google Scholar 

  90. Antonelli, G., Giannelli, G., Pistello, M., Maggi, F., Vatteroni, L., Currenti, M., Del Vecchio, S., Roffi, L., Pastore, G., and Dianzani, F. (1994) Clinical significance of recombinant interferon-alpha 2 neutralizing antibodies in hepatitis patients. J. Interferon Res. 14 (4), 211–213.

    PubMed  CAS  Google Scholar 

  91. Capalbo, M., Palmisano, L., Bonino, F., Pellas, C., and Maset, J. (1994) Intramuscular natural beta interferon in the treatment of chronic hepatitis B: a multicentre trial. Italian Hepatitis B Study Group. Ital. J. Gastroenterol. 26 (5), 238–241.

    PubMed  CAS  Google Scholar 

  92. Kagawa, T., Morizane, T., Saito, H., Tsunematsu, S., Tada, S., Kumagai, N., Tsuchimoto, K., Sugiura, H., Mukai, M., and Tsuchiya, M. (1993) A pilot study of long-term weekly interferon-beta administration for chronic hepatitis B. (See comments) Amer. J. Gastroenterol. 88 (2), 212–216.

    CAS  Google Scholar 

  93. Lau, J. Y., Lai, C. L., Wu, P. C., Chung, H. T., Lok, A. S., and Lin, H. J. (1991) A randomised controlled trial of recombinant interferon-gamma in Chinese patients with chronic hepatitis B virus infection. J. Med. Virol. 34 (3), 184–187.

    PubMed  CAS  Google Scholar 

  94. Ruiz-Moreno, M., Rua, M. J., Moraleda, G., Guardia, L., Moreno, A., and Carreno, V. (1992) Treatment with interferon gamma versus interferons alfa and gamma in children with chronic hepatitis B. Pediatrics 90 (2 Pt 1), 254–258.

    PubMed  CAS  Google Scholar 

  95. Kakumu, S., Ishikawa, T., Mizokami, M., Orido, E., Yoshioka, K., Wakita, T., and Yamamoto, M. (1991) Treatment with human gamma interferon of chronic hepatitis B: comparative study with alpha interferon. J. Med. Virol. 35 (1), 32–37.

    PubMed  CAS  Google Scholar 

  96. Di Bisceglie, A. M., Rustgi, V. K., Kassianides, C., Lisker-Melman, M., Park, Y., Waggoner, J. G., and Hoofnagle, J. H. (1990) Therapy of chronic hepatitis B with recombinant human alpha and gamma interferon. Hepatology 11 (2), 266–270.

    PubMed  Google Scholar 

  97. Pardoll, D. M. (1995) Paracrine cytokine adjuvants in cancer immunotherapy (review). Annu. Rev. Immunol. 13, 399–415.

    PubMed  CAS  Google Scholar 

  98. Martin, J., Bosch, O., Moraleda, G., Bartolome, J., Quiroga, J. A., and Carreno, V. (1993) Pilot study of recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of chronic hepatitis B. Hepatology 18 (4), 775–780.

    PubMed  CAS  Google Scholar 

  99. Silva, M., Perez, V., Manero, E., Escoms, S., Tanno, H., Bariletto, S., and Albrecht, J. (1994) GM-CSF plus interferon in chronic hepatitis B patients who failed previous interferon therapy. Hepatology 20 (4 Part 2), 300.

    Google Scholar 

  100. Abbas, A. K., Lichtman, A. H., and Pober, J. S. (1991) Cellular and Molecular Immunology, W. B. Saunders, Philadelphia, PA.

    Google Scholar 

  101. Onji, M., Kondoh, H., Horiike, N., Yamaguchi, S., Ogawa, Y., Kumon, I., and Ohta, Y. (1987) Effect of recombinant interleukin 2 on hepatitis B e antigen positive chronic hepatitis. Gut 28 (12), 1648–1652.

    PubMed  CAS  Google Scholar 

  102. Nishioka, M., Kagawa, H., Shirai, M., Terada, S., and Watanabe, S. (1987) Effects of human recombinant interleukin 2 in patients with chronic hepatitis B: a preliminary report. Amer. J. Gastroenterol. 82 (5), 438–442.

    CAS  Google Scholar 

  103. Bruch, H. R., Korn, A., Klein, H., Markus, R., Malmus, K., Baumgarten, R., and Muller, R. (1993) Treatment of chronic hepatitis B with interferon alpha-2b and interleukin-2. J. Hepatol. 17 (Suppl. 3), S52 - S55.

    PubMed  Google Scholar 

  104. Tilg, H., Vogel, W., Tratkiewicz, J., Aulitzky, W. E., Herold, M., Gruber, M., Geissler, D., Umlauft, E, Judmaier, G., Schwulera, U., et al. (1993) Pilot study of natural human interleukin-2 in patients with chronic hepatitis B. J. Hepatol. 19 (2), 259–267.

    PubMed  CAS  Google Scholar 

  105. Trinchieri, G. (1995) Interleukin-12, a proinflammatory cytokine with immunoregulatory functions. Annu. Rev. Immunol. 13, 251–276.

    PubMed  CAS  Google Scholar 

  106. Rasi, G., Mutchnik, M. G., DiVirgilio, D., Sinibaldi-Vallebona, P., Pierimarchi, P., Colella, F., Favalli, C., and Garaci, E. (1996) Combination low-dose lymphoblastoid interferon and thymosin-al therapy in the treatment of chronic hepatitis B. J. Viral Hepatitis 3, 191–196.

    CAS  Google Scholar 

  107. Gish, R. G., and Keeffe, E. B. (1995) Recent developments in the treatment of chronic hepatitis B virus infection. Exp. Opin. Invest. Drugs 4 (2), 95–115.

    CAS  Google Scholar 

  108. O’Brien, C. B., Garcia, G., Henzel, B., Martin, M., Ladenheim, J., Ginsberg, G., Hubbell, H., Strayer, D., and Carter, W. (1994) Ampligen treatment of chronic hepatitis B. Gastroenterology 106(4 Suppl.), 952.

    Google Scholar 

  109. Renoux, G. (1980) The general immunopharmacology of levamisole (review). Drugs 20 (2), 89–99.

    PubMed  CAS  Google Scholar 

  110. Taki, H. N., and Schwartz, S. A. (1994) Levamisole as an immunopotentiator for T cell deficiency. Immunopharmacol. Immunotoxicol. 16 (2), 129–137.

    PubMed  CAS  Google Scholar 

  111. Ruiz-Moreno, M., Garcia, R., Rua, M. J., Serrano, B., Moraleda, G., Feijoo, E., Bartolome, J., Ortiz, F., Castillo, I., and Carreno, V. (1993) Levamisole and interferon in children with chronic hepatitis B. Hepatology 18 (2), 264–269.

    PubMed  CAS  Google Scholar 

  112. Fattovich, G., Giustina, G., Brollo, L., Guido, M., Pontisso, P., Noventa, F., and Alberti, A. (1992) Therapy for chronic hepatitis B with lymphoblastoid interferon-alpha and levamisole. Hepatology 16 (5), 1115–1119.

    PubMed  CAS  Google Scholar 

  113. Bosch, O., Moraleda, G., Castillo, I., and Carreno, V. (1993) Treatment of chronic hepatitis B with recombinant interferon alpha versus recombinant interferon alpha plus levamisole. J. Hepatol. 19 (3), 437–441.

    PubMed  CAS  Google Scholar 

  114. Thyagarajan, S. P., Subramanian, S., andThirunalasundari, T. (1988) Effect of Phyllanthus amarus on chronic carriers of hepatitis B virus. Lancet 2 (8614), 764–766.

    PubMed  CAS  Google Scholar 

  115. Thyagarajan, S. P., Jayaram, S., Valliammai, T., and Madanagopalan (1990) Phyllanthus amarus and hepatitis B. (Letter; comment) Lancet 336 (8720), 949–950.

    PubMed  CAS  Google Scholar 

  116. Wang, M., Cheng, H., Li, Y., Meng, L., Zhao, G., and Mai, K. (1995) Herbs of the genus Phyllanthus in the treatment of chronic hepatitis B: observations with three preparations from different geographic sites. J. Lab. Clin. Med. 126 (4), 350–352.

    PubMed  CAS  Google Scholar 

  117. Milne, A., Hopkirk, N., Lucas, C. R., Waldon, J., and Foo, Y. (1994) Failure of New Zealand hepatitis B carriers to respond to Phyllanthus amarus. N. Zealand Med. J. 107 (980), 243.

    CAS  Google Scholar 

  118. Doshi, J. C., Vaidya, A. B., Antarkar, D. S., Deolalikar, R., and Antani, D. H. (1994) A two-stage clinical trial of Phyllanthus amarus in hepatitis B carriers: failure to eradicate the surface antigen. Indian. J. Gastroenterol. 13 (1), 7–8.

    PubMed  CAS  Google Scholar 

  119. Thamlikitkul, V., Wasuwat, S., and Kanchanapee, P. (1991) Efficacy of Phyllanthus amarus for eradication of hepatitis B virus in chronic carriers. J. Med. Assoc. Thailand 74 (9), 381–385.

    CAS  Google Scholar 

  120. Niu, J. Z., Wang, Y. Y., Qiao, M., Gowans, E., and Edwards, P. (1990) Effect of Phyllanthus amarus on duck hepatitis B virus replication in vivo. J. Med. Virol. 32 (4), 212–218.

    PubMed  CAS  Google Scholar 

  121. Kakumu, S., Yoshioka, K., Wakita, T., Ishikawa, T., Takayanagi, M., and Higashi, Y. (1993) Pilot study of ribavirin and interferon-beta for chronic hepatitis B. Hepatology 18 (2), 258–263.

    PubMed  CAS  Google Scholar 

  122. Fried, M. W., Fong, T. L., and Swain, M. G. (1992) Hepatitis B virus (HBV) DNA suppression during long-term therapy with ribavirin. Gastroenterology 102, A808.

    Google Scholar 

  123. Berk, L., Schalm, S. W., de Man, R. A., Heytink, R. A., Berthelot, P., Brechot, C., Boboc, B., Degos, E, Marcellin, P., Benhamou, J. P., et al. (1992) Failure of acyclovir to enhance the antiviral effect of alpha lymphoblastoid interferon on HBeseroconversion in chronic hepatitis B. A multi-centre randomized controlled trial. J. Hepatol. 14 (2–3), 305–309.

    PubMed  CAS  Google Scholar 

  124. Alexander, G. J., Fagan, E. A., Hegarty, J. E., Yeo, J., and Eddleston (1987) Controlled clinical trial of acyclovir in chronic hepatitis B virus. J. Med. Virol. 21 (1), 81–87.

    PubMed  CAS  Google Scholar 

  125. Janssen, H. L., Berk, L., Heijtink, R. A., ten Kate, F. J., and Schalm, S. W. (1993) Interferon-alpha and zidovudine combination therapy for chronic hepatitis B: results of a randomized, placebo-controlled trial. Hepatology 17 (3), 383–388.

    PubMed  CAS  Google Scholar 

  126. Chossegros, P., Pouteil-Noble, C., Samuel, D., Causse, X., Ouxan D., Bizollon T., Touraine J. L., and Trepo C. (1993) Ganciclovir is an effective antiviral agent for post-transplant chronic HBV infections; maintenance therapy may be required in some cases. Gastroenterology 104(4 Suppl.), 888.

    Google Scholar 

  127. De La Mata, M., Montero, J. L., Fraga, E., Costan, G., Delgado, M., Lopez, P., Gonzalez, R., Pera, C., and Mino, G. (1995) Efficacy of ganciclovir in the treatment of hepatitis B virus infection of the liver graft: Long-term results. Hepatology 22 (4 Part 2 ), 130.

    Google Scholar 

  128. McKenzie, R., Fried, M. W., Sallie, R., Conjeevaram, H., Di Bisceglie, A. M., Park, Y., Savarese, B., Kleiner, D., Tsokos, M., Luciano, C., et al.. (1995) Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. (See comments) N. Engl. J. Med. 333(17) 1099–1105.

    PubMed  CAS  Google Scholar 

  129. Hoofnagle, J., McKenzie, R., and Straus, S. (1995) Severe toxicity of fialuridine (FIAU) (Letter). N. Engl. J. Med. 334, 1137.

    Google Scholar 

  130. Fried, M. W., DiBisceglie, A. M., Straus, S. E., Savarese, B., Beames, M. P., and Hoofnagle, J. H. (1992) FIAU, a new oral anti-viral agent, profoundly inhibits HBV DNA in patients with chronic hepatitis B. Hepatology 16, 127A.

    Google Scholar 

  131. Dienstag, J. L., Perrillo, R. P., Schiff, E. R., and Bartholomew, M. (1995) A preliminary trial of lamivudine for chronic hepatitis B infection. N. Engl. J. Med. 333 (25), 1657–1661.

    PubMed  CAS  Google Scholar 

  132. Lai, C. L., Ching, C. K., Tung, A., Hill, A. M., Wong, B. C. Y., Lim, S. P., Dent, J. C., and Wu, P. C. (1994) Short term lamivudine suppresses HBV DNA in Chinese HBsAg carriers. Hepatology 20(4 Part 2 ), 298.

    Google Scholar 

  133. Grellier, L., Mutimer, D., Ahmed, M., Brown, D., Burroughs, A. K., Rolles, K., McMaster, P., Beranek, P., Kennedy, F., Kibbler, H., McPhillips, P., Elias, E., and Dusheiko, G. (1996) Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 348, 1212–1215.

    PubMed  CAS  Google Scholar 

  134. Woolf, G. M., Wagner, D. A., Makowka, L., and Vierling, J. M. (1995) Quantitative liver function testing pre-and post-liver transplantation (LT). Hepatology 22 (4 Part 2), 510.

    Google Scholar 

  135. Gutfreund, K. S., Fischer, K. P., Tipples, G., Ma, M., Bain, V. G., Kneteman, N., Tyrrell, D. L. J. (1995) Lamivudine results in a complete and sustained suppression of hepatitis B virus replication in patients requiring orthotopic liver transplantation for cirrhosis secondary to hepatitis B. Hepatology 22 (4 Part 2), 328.

    Google Scholar 

  136. Ling, R., Mutimer, D., Ahmed, M., Boxall, E. H., Elias, E., Dusheiko, G. M., and Harrison, T. J. (1996) Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 24, 711–713.

    PubMed  CAS  Google Scholar 

  137. Tipples, G. A., Ma, M. M., Fischer, K. P., Bain, V. G., Kneteman, N. M., and Tyrrell, D. L. (1996) Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 24, 714–717.

    CAS  Google Scholar 

  138. Tisdale, M., Kemp, S. D., Parry, N. R., Larder, B. A. (1993) Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3’-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. USA 90 (12), 5653–5656.

    PubMed  CAS  Google Scholar 

  139. Boker, K. H., Ringe, B., Kruger, M., Pichlmayr, R., and Manns, M. P. (1994) Prostaglandin E plus famciclovir—a new concept for the treatment of severe hepatitis B after liver transplantation. Transplantation 57 (12), 1706–1708.

    CAS  Google Scholar 

  140. Tillman, H. L., Trautwein, C. H., Bode, U., Oldhafer, K., Boker, K., Pichlmayr, R., and Manns, M. P. (1994) Treatment of hepatitis B virus reinfection after liver transplantation with famciclovir. Hepatology 20, 130.

    Google Scholar 

  141. Main, J., Brown, J. L., Howells, C., Galassini, R., Crossey, M., Karayiannis, P., Georgiou, P., Atkinson, G., and Thomas, H. C. (1996) A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J. Viral. Hep. 3, 211–215.

    CAS  Google Scholar 

  142. Zoulim, F., Dannaoui, E., and Trepo, C. (1995) Inhibitory effect of penciclovir, the active metabolite of famciclovir on the priming of hepadnavirus reverse transcriptase. Hepatology 22, 329A.

    Google Scholar 

  143. Vitiello, A., Ishioka, G., Grey, H. M., Rose, R., Farness, P., LaFond, R., Yuan, L., Chisari, F. V., Furze, J., Bartholomeuz, R., et al. (1995) Development of a lipopeptidebased therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J. Clin. Invest. 95 (1), 341–349.

    PubMed  CAS  Google Scholar 

  144. Madon, J., and Blum, H. E. (1995) Adenovirus-associated receptor-mediated delivery of hepatitis B virus DNA and oligonucleotides to liver cells. Hepatology 22, 263A.

    Google Scholar 

  145. Nakazono, K., Wu, C. H., and Wu, G. Y. (1994) Targeted administration of antisense DNA inhibits subsequent HBV transfection in vitro. Hepatology 20, 203A.

    Google Scholar 

  146. Nunes, F. A. and Raper, S. E. (1996) Liver-directed gene therapy (review). Med. Clin. N. Amer. 80 (5), 1201–1213.

    PubMed  CAS  Google Scholar 

  147. Choo, Q. L., Kuo, G., Weiner, A. J., Overby, L. R., Bradley, D. W., and Houghton, M. (1989) Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244 (4902), 359–362.

    PubMed  CAS  Google Scholar 

  148. Alter, M. J., and Sampliner, R. E. (1989) Hepatitis C: and miles to go before we sleep. (Editorial) N. Engl. J. Med. 321 (22), 1538–1540.

    PubMed  CAS  Google Scholar 

  149. Zeldis, J. B., and Jensen, P. (1994) Hepatitis C virus pathogenicity: the corner pieces of the jigsaw puzzle are found. (Editorial; comment) Gastroenterology 106 (4),1118–1120.

    Google Scholar 

  150. Hoofnagle, J. H., Mullen, K. D., Jones, D. B., Rustgi, V., Di Bisceglie, A., Peters, M., Waggoner, J. G., Park, Y., and Jones, E. A. (1986) Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N. Engl. J. Med. 315 (25), 1575–1578.

    PubMed  CAS  Google Scholar 

  151. Shindo, M., Di Bisceglie, A. M., and Hoofnagle, J. H. (1992) Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon. Hepatology 15 (6), 1013–1016.

    PubMed  CAS  Google Scholar 

  152. Tine, F., Magrin, S., Craxi, A., and Pagliaro, L. (1991) Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials. J. Hepatol. 13 (2), 192–199.

    PubMed  CAS  Google Scholar 

  153. Romeo, R., Stanislas, P., Berthelot, P., and Brechot, C. (1994) Eradication of hepatitis C virus RNA after alpha-interferon therapy. Ann. Int. Med. 121, 276–277.

    PubMed  CAS  Google Scholar 

  154. Davis, G. L., and Lau, J. Y. (1995) Choice of appropriate end points of response to interferon therapy in chronic hepatitis C virus infection (review). J. Hepatol. 22 (1 Suppl), 110–114.

    PubMed  CAS  Google Scholar 

  155. Aiyama, T., Yoshioka, K., Hirofuji, H., Kusakabe, A., Yamada, M., Tanaka, K., and Kakumu, S. (1994) Changes in serum hepatitis C virus RNA titer and response to interferon therapy in patients with chronic hepatitis C. Dig. Dis. Sci. 39 (10), 2244–2249.

    PubMed  CAS  Google Scholar 

  156. Kakumu, S., Yoshika, K., Tanaka, K., Higashi, Y., Kurokawa, S., Hirofuji, H., and Kusakabe, A. (1993) Long-term carriage of hepatitis C virus with normal aminotransferase after interferon treatment in patients with chronic hepatitis C. J. Med. Virol. 41 (1), 65–70.

    PubMed  CAS  Google Scholar 

  157. Matsushita, E., Unoura, M., and Kobayashi, K. (1994) Psychiatric complications of interferon therapy. Japan J. Clin. Med. 52 (7), 1910–1913.

    CAS  Google Scholar 

  158. Levenson, J. L., and Fallon, H. J. (1993) Fluoxetine treatment of depression caused by interferon-alpha. Amer. J. Gastroenterol. 88 (5), 760–761.

    CAS  Google Scholar 

  159. Okuno, H., Hirota, T., Shiozaki, Y., Inoue, K., Hagihara, M., Sugasawa, K., and Okami, T. (1994) Interferon-associated retinopathy (review). Jpn. J. Clin. Med. 52 (7), 1919–1923.

    CAS  Google Scholar 

  160. Soushi, S., Kobayashi, F., Obazawa, H., Kigasawa, K., Shiraishi, K., Itakura, M., and Matsuzaki, S. (1996) Evaluation of risk factors of interferon-associated retinopathy in patients with type C chronic active hepatitis. Acta Societatis Ophthalmol. Jpn. 100 (1), 69–76.

    CAS  Google Scholar 

  161. Kawano, T., Shigehira, M., Uto, H., Nakama, T., Kato, J., Hayashi, K., Maruyama, T., Kuribayashi, T., Chuman, T., Futami, T., and Tsubouchi, H. (1996) Retinal complications during interferon therapy for chronic hepatitis C. Amer. J. Gastroenterol. 91 (2), 309–913.

    CAS  Google Scholar 

  162. Chuman, T., Nao-i, N., Sawada, A., Kawano, T., and Shigehira, M. (1994) Interferon-induced retinal changes. (Japanese). Acta Societatis Ophthalmol. Jpn. 98 (6), 616–621.

    CAS  Google Scholar 

  163. Abe, T., Nakajima, A., Satoh, N., Koizumi, T., Sakuragi, S., Fujimori, K., Ono, T., Kuramitsu, T., Komatsu, M., and Masamune, O. (1995) Incidence of eye lesions in patients with chronic hepatitis C. Rinsho Ganka 49 (3), 391–394.

    Google Scholar 

  164. Poynard, T., Leroy, V., Cohard, M., Thevenot, T., Mathurin, P., Opolon, P., and Zarski, J. (1996) Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 24 (4), 778–789.

    PubMed  CAS  Google Scholar 

  165. Matsuda, J., Saitoh, N., Gotoh, M., Gohchi, K., Tsukamoto, M., Syoji, S., Miyake, K., and Yamanaka, M. (1995) High prevalence of anti-phospholipid antibodies and anti-thyroglobulin antibody in patients with hepatitis C virus infection treated with interferon-alpha. Amer. J. Gastroenterol. 90 (7), 1138–1141.

    CAS  Google Scholar 

  166. Baudin, E., Marcellin, P., Pouteau, M., Colas-Linhart, N., Le Floch, J. P., Lemmonier, C., Benhamou, J. P., and Bok, B. (1993) Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C. Clin. Endocrinol. 39 (6), 657–661.

    CAS  Google Scholar 

  167. Nagayama, Y., Ohta, K., Tsuruta, M., Takeshita, A., Kimura, H., Hamasaki, K., Ashizawa, K., Nakata, K., Yokoyama, N., and Nagataki, S. (1994) Exacerbation of thyroid autoimmunity by interferon alpha treatment in patients with chronic viral hepatitis: our studies and review of the literature (review). Endocrin. J. 41 (5), 565–572.

    CAS  Google Scholar 

  168. Watanabe, U., Hashimoto, E., Hisamitsu, T., Obata, H., and Hayashi, N. (1994) The risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C. (See comments) Amer. J. Gastroenterol. 89 (3), 399–403.

    CAS  Google Scholar 

  169. Fried, M. W. and Hoofnagle, J. H. (1995) Therapy of hepatitis C (review). Sem. Liv. Dis. 15 (1), 82–91.

    CAS  Google Scholar 

  170. Lin, R., Schoeman, M. N., Craig, P. I. Bilous, M., Grierson, J., McDonald, J. A., Batey, R. G., and Farrell, G. C. (1991) Can the response to interferon treatment be predicted in patients with chronic active hepatitis C? Austral. N. Zealand J. Med. 21(3) 387–392.

    CAS  Google Scholar 

  171. Pagliaro, L., Craxi, A., Cammaa, C., Tine, F., Di Marco, V., Lo Iacono, O., and Almasio, P. (1994) Interferon-alpha for chronic hepatitis C: an analysis of pretreatment clinical predictors of response. Hepatology 19 (4), 820–828.

    PubMed  CAS  Google Scholar 

  172. Jouet, P., Roudot-Thoraval, F., Dhumeaux, D., and Metreau, J. M. (1994) Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Gastroenterology 106 (3), 686–690.

    PubMed  CAS  Google Scholar 

  173. Yuki, N., Hayashi, N., Kasahara, A., Hagiwara, H., Takehara, T., Oshita, M., Katayama, K., Fusamoto, H., and Kamada, T. (1995) Pretreatment viral load and response to prolonged interferon-alpha course for chronic hepatitis C. J. Hepatol. 22 (4), 457–463.

    PubMed  CAS  Google Scholar 

  174. Lau, J. Y., Davis, G. L., Kniffen, J., Mizokami, M., Ohno, T., and Diamond, D. A. (1993) Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 341, 1501–1504.

    PubMed  CAS  Google Scholar 

  175. Stuyver, L., Wyseur, A., van Arnhem, W., Lunel, F., Laurent-Pui, P., Pawlotsky, J. M., Kleter, B., Bassit, L., Nkengasong, J., van Doom, L. J., and Maertens, G. (1995) Hepatitis C virus genotyping by means of 5’-UR/core line probe assays and molecular analysis of untypeable samples. Virus Res. (38), 137–157.

    Google Scholar 

  176. Mahaney, K., Tedeschi, V., Maertens, G., Di Bisceglie, A. M., Vergalla, J., Hoofnagle, J. H., and Sallie, R. (1994) Genotypic analysis of hepatitis C virus in American patients. Hepatology 20 (6), 1405–1411.

    PubMed  CAS  Google Scholar 

  177. Chemello, L., Bonetti, P., Cavalletto, L., Talato, F., Donadon, V., Casarin, P., Belussi, F., Frezza, M., Noventa, F., Pontisso, P., et al. (1995) Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. The Triveneto Viral Hepatitis Group. Hepatology 22 (3), 700–706.

    PubMed  CAS  Google Scholar 

  178. Marcellin, P., Boyer, N., Pouteau, M., Benhamou, J. P., and Erlinger, S. (1994) Retreatment with interferon-alpha of chronic hepatitis C virus infection (letter; comment). Lancet 344 (8923), 690–691.

    PubMed  CAS  Google Scholar 

  179. Lebovics, E., Lantin, J., Chaurushia, G., Dworkin, B. M., Casellas, A., and Rosenthal, W. S. (1995) The breakthrough phenomenon during alpha-interferon therapy of chronic hepatitis C: incidence, management, and outcome. Amer. J. Gastroenterol. 90 (6), 951–954.

    CAS  Google Scholar 

  180. Diodati, G., Bonetti, P., Noventa, F., Casarin, C., Rugge, M., Scaccabarozzi, S., Tagger, A., Pollice, L., Tremolada, F., Davite, C., et al. (1994) Treatment of chronic hepatitis C with recombinant human interferon-alpha 2a: results of a randomized controlled clinical trial. Hepatology 19 (1), 1–5.

    PubMed  CAS  Google Scholar 

  181. Finkelstein, S.D., Sayegh, R., Uchman, S., Christensen, S., and Swalsky, P. (1992) HCV undergoes extensive mutational change in NS5 region in association with relapse-breakthrough following alpha interferon therapy. Hepatology 16(4 Part 2 ), 132A.

    Google Scholar 

  182. Roffi, L., Mels, G. C., Antonelli, G., Bellati, G., Panizzuti, F., Piperno, A., Pozzi, M., Ravizza, D., Angeli, G., Dianzani, F., et al. (1995) Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: prevalence, etiology, and management. Hepatology 21 (3), 645–649.

    PubMed  CAS  Google Scholar 

  183. Antonelli, G., Giannelli, G., Currenti, M., Simeoni, E., Del Vecchio, S., Maggi, F., Pistello, M., Roffi, L., Pastore, G., Chemello, L., and Dianzani, F. (1996) Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-alpha-2 therapy. Clin. Exp. Immunol. 104 (3), 384–387.

    PubMed  CAS  Google Scholar 

  184. Olaso, V., Siles, M., Cordoba, J., Gisbert, C., Berenguer, M., Benages, R., and Berenguer, J. (1995) (Prevalence and clinical significance of autoantibodies in chronic hepatitis C treated with interferon alfa). (Spanish). Rev. Esp. Enferm. Dig. 87(8) 577–581.

    PubMed  CAS  Google Scholar 

  185. Marcellin, P., and Benhamou, J. P. (1994) Treatment of chronic viral hepatitis (review). Baillieres Clin. Gastroenterol. 8 (2), 233–253.

    PubMed  CAS  Google Scholar 

  186. Poynard, T., Bedossa, P., Chevallier, M., Mathurin, P., Lemonnier, C., Trepo, C., Couzigou, R, Payen, J. L., Sajus, M., Costa, J. M., et al. (1995) A comparison of three interferon alpha-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N. Engl. J. Med. 332 (22), 1457–1462.

    PubMed  CAS  Google Scholar 

  187. Mitsui, T., Iwano, K., Masuko, K., Yamazaki, C., Okamoto, H., Tsuda, F., Tanaka, T., and Mishiro, S. (1992) Hepatitis C virus infection in medical personnel after needlestick accident. (See comments) Hepatology 16 (5), 1109–1114.

    PubMed  CAS  Google Scholar 

  188. Lampertico, P., Rumi, M., Romeo, R., Craxi, A., Soffredini, R., Biassoni, D., and Colombo, M. (1994) A multicenter randomized controlled trial of recombinant interferon-alpha 2b in patients with acute transfusion-associated hepatitis C. Hepatology 19 (1), 19–22.

    PubMed  CAS  Google Scholar 

  189. Takano, S., Satomura, Y., Omata, M. (1994) Effect of interferon beta on non-A, non-B acute hepatitis: a prospective, randomized, controlled-dose study. Japan Acute Hepatitis Cooperative Study Group. Gastroenterology 107, 805–811.

    PubMed  CAS  Google Scholar 

  190. Viladomiu, L., Genesca, J., Esteban, J. I., Allende, H., Gonzalez, A., Lopez-Talavera, J. C., Esteban, R., and Guardia, J. (1992) Interferon-alpha in acute posttransfusion hepatitis C: a randomized, controlled trial. Hepatology 15 (5), 767–769.

    PubMed  CAS  Google Scholar 

  191. Hwang, S. J., Lee, S. D., Chan, C.Y., Lu, R. H., and Lo, K. J. (1994) A randomized controlled trial of recombinant interferon alpha-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C. J. Hepatol. 21 (5), 831–836.

    PubMed  CAS  Google Scholar 

  192. Naito, M., Hayashi, N., Hagiwara, H., Hiramatsu, N., Kasahara, A., Fusamoto, H., and Kamada, T. (1994) Serum hepatitis C virus RNA quantity and histological features of hepatitis C virus carriers with persistently normal ALT levels. Hepatology 19 (4), 871–875.

    PubMed  CAS  Google Scholar 

  193. Coltorti, M., Romano, M., Persico, M., Morisco, F., Tuccillo, C., and Caporaso, N. (1995) Hepatitis C virus RNA in serum and liver histology in asymptomatic antiHCV positive subjects. Infection 23 (1), 33–36.

    PubMed  CAS  Google Scholar 

  194. Sangiovanni, A., Spinzi, G. C., Ceriani, R., Prada, A., Bissoli, F., Morales, R., Casiraghi, M. A., Sciariada, L., Colombo, E., Fossati, M., and Minoli, G. (1995) Randomized controlled trial of HCV healthy carriers treatment with interferon (IFN). Hepatology 22 (4 Part 2), 290A.

    Google Scholar 

  195. Altraif, I. H., Abdulla, A. S., al Sebayel, M. I., Said, R. A., al Suhaibani, M. O., and Jones, A. A. (1995) Hepatitis C associated glomerulonephritis. Amer. J. Nephrol. 15 (5), 407–410.

    CAS  Google Scholar 

  196. Stehman-Breen, C., Alpers, C. E., Couser, W. G., Willson, R., and Johnson, R. J. (1995) Hepatitis C virus associated membranous glomerulonephritis. Clin. Nephrol. 44 (3), 141–147.

    PubMed  CAS  Google Scholar 

  197. Johnson, R. J., Gretch, D. R., Couser, W. G., Alpers, C. E., Wilson, J., Chung, M., Hart, J., and Wilson, R. (1994) Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy. Kidney Intern. 46 (6), 1700–1704.

    CAS  Google Scholar 

  198. Rostaing, L., Izopet, J., Baron, E., Duffaut, M., Puel, J., Durand, D., and Suc, J. M. (1995) Preliminary results of treatment of chronic hepatitis C with recombinant interferon alpha in renal transplant patients. Nephrol. Dialysis Transplant. 10 (Suppl. 6), 93–96.

    Google Scholar 

  199. Kakimoto, K., Takahara, S., Kokado, Y., Kameoka, H., Ishibashi, M., Okuyama, A., Kyo, M., and Nagano, S. (1994) (A case of allograft rejection induced by the interferon-alpha therapy to hepatitis type C after renal transplantation). (Japanese). Acta Urol. Japan 40(6) 529–532.

    CAS  Google Scholar 

  200. Takahara, S., Kakimoto, K., Kokado, Y., Kameoka, H., Ishibashi, M., Kawada, S., Kyo, M., Nagano, S., Mikami, O., and Okuyama, A. (1995) Interferon alpha therapy for chronic active hepatitis type C after renal transplantation and allograft rejection. Intern. Urol. Nephrol. 27 (4), 479–485.

    CAS  Google Scholar 

  201. Feray, C., Samuel, D., Gigou, M., Paradis, V., David, M. F., Lemonnier, C., Reynes, M., and Bismuth, H. (1995) An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Hepatology 22 (4 Pt 1), 1084–1089.

    PubMed  CAS  Google Scholar 

  202. Wright, T. L., Combs, C., Kim, M., Ferrell, L., Bacchetti, P., Ascher, N., Roberts, J., Wilber, J., Sheridan, P., and Urdea, M. (1994) Interferon-alpha therapy for hepatitis C virus infection after liver transplantation. Hepatology 20 (4 Pt. 1), 773–779.

    PubMed  CAS  Google Scholar 

  203. Gane, E. J., Tibbs, C. J., Ramage, J. K., Portmann, B. C., and Williams, R. (1995) Ribavirin therapy for hepatitis C infection following liver transplantation. Transpl. Intern. 8 (1), 61–64.

    CAS  Google Scholar 

  204. Cattral, M. S., Krajden, M., Wanless, I. R., Rezig, M., Cameron, R., Greig, P. D., Chung, S. W., and Levy, G. A. (1996) A pilot study of ribavirin therapy for recurrent hepatitis C virus infection after liver transplantation. Transplantation 61 (10), 1483–1488.

    PubMed  CAS  Google Scholar 

  205. Shiell, A., Briggs, A., and Farrell, G. C. (1994) The cost effectiveness of alpha interferon in the treatment of chronic active hepatitis C. (See comments) Med. J. Australia 160 (5), 268–272.

    PubMed  CAS  Google Scholar 

  206. Nishiguchi, S., Kuroki, T., Nakatani, S., Morimoto, H., Takeda, T., Nakajima, S., Shiomi, S., Seki, S., Kobayashi, K., and Otani, S. (1995) Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. (See comments) Lancet 346 (8982), 1051–1055.

    PubMed  CAS  Google Scholar 

  207. Perez, R., Pravia, R., Artimez, M. L., Giganto, F., Rodriguez, M., Lombrana, J. L., and Rodrigo, L. (1995) Clinical efficacy of intramuscular human interferon-beta vs interferon-alpha 2b for the treatment of chronic hepatitis C. J. Viral Hep. 2 (2), 103–106.

    CAS  Google Scholar 

  208. Kobayashi, Y., Watanabe, S., Konishi, M., Yokoi, M., Kakehashi, R., Kaito, M., Kondo, M., Hayashi, Y., Jomori, T., and Suzuki, S. (1993) Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon-beta. Hepatology 18 (6), 1319–1325.

    PubMed  CAS  Google Scholar 

  209. Di Bisceglie, A. M., Shindo, M., Fong, T. L., Fried, M. W., Swain, M. G., Bergasa, N. V., Axiotis, C. A., Waggoner, J. G., Park, Y., and Hoofnagle, J. H. (1992) A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 16 (3), 649–654.

    PubMed  Google Scholar 

  210. Di Bisceglie, A. M., Conjeevaram, H. S., Fried, M. W., Sallie, R., Park, Y.,Yurdaydin, C., Swain, M., Kleiner, D. E., Mahaney, K., and Hoofnagle, J. H. (1995) Ribavirin as therapy for chronic hepatitis C: A randomized, double-blind, placebo-controlled trial. Ann. Int. Med. 123 (12), 897–903.

    CAS  Google Scholar 

  211. Brillanti, S., Garson, J., Foli, M., Whitby, K., Deaville, R., Masci, C., Miglioli, M., and Barbara, L. (1994) A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 107 (3), 812–807.

    PubMed  CAS  Google Scholar 

  212. Schvarcz, R., Yun, Z. B., Sonnerborg, A., and Weiland, O. (1995) Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone. J. Med. Virol. 46 (1), 43–47.

    PubMed  CAS  Google Scholar 

  213. Wakita, T., and Wands, J. R. (1994) Specific inhibition of hepatitis C virus expression by antisense oligodeoxynucleotides: in vitro model for selection of target sequence. J. Biol. Chem. 269 (19), 14205–14210.

    PubMed  CAS  Google Scholar 

  214. Hanecak, R., Brown Driver, V., Fox, M. C., Azad, R. F., Furusako, S., Nozaki, C., Ford, C., Sasmor, H., and Anderson, K. P. (1996) Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes. J Virol. 70 (8), 5203–5212.

    PubMed  CAS  Google Scholar 

  215. Moradpour, D., Englert, C., Wakita, T., and Wands, J. R. (1996) Characterization of cell lines allowing tightly regulated expression of hepatitis C virus core protein. Virology 222 (1), 51–63.

    PubMed  CAS  Google Scholar 

  216. Alt, M., Renz, R., Hofschneider, P. H., Paumgartner, G., and Caselmann, W. H. (1995) Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides. Hepatology 22 (3), 707–717.

    PubMed  CAS  Google Scholar 

  217. Mizutani, T., Kato, N., Hirota, M., Sugiyama, K., Murakami, A., and Shimotohno, K. (1995) Inhibition of hepatitis C virus replication by antisense oligonucleotide in culture cells. Biochem. Biophys. Res. Commun. 212 (3), 906–911.

    PubMed  CAS  Google Scholar 

  218. Branch, A. D. (1996) A hitchhiker’s guide to antisense and nonantisense biochemical pathways. Hepatology 24 (6), 1517–1529.

    PubMed  CAS  Google Scholar 

  219. Smith, J. P. (1996) Treatment of chronic hepatitis C with amantadine-hydrochloride. Gastroenterology 110(4 Suppl.), 1330 A.

    Google Scholar 

  220. Hong, Z., Ferrari, E., Wright Minogue, J., Chase, R., Risano, C., Seelig, G., Lee, C. G., and Kwong, D. (1996) Enzymatic characterization of hepatitis C virus NS3/4A complexes expressed in mammalian cells by using the herpes simplex virus amplicon system. J. Virol. 70 (7), 4261–4268.

    PubMed  CAS  Google Scholar 

  221. Hahm, B., Han, D. S., Back, S. H., Song, O. K., Cho, M. J., Kim, C. J., Shimotohno, K., and Tang, S. K. (1995) NS3–4A of hepatitis C virus is a chymotrypsin-like protease. J. Virol. 69 (4), 2534–2539.

    PubMed  CAS  Google Scholar 

  222. Tomei, L., Failla, C., Vitale, R. L., Bianchi, E., and De Francesco, R. (1996) A central hydrophobic domain of the hepatitis C virus NS4A protein is necessary and sufficient for the activation of the NS3 protease. J. Gen. Virol. 77 (5), 1065–1070.

    PubMed  CAS  Google Scholar 

  223. Sakamoto, N., Wu, C. H., and Wu, G. Y. (1995) Inhibition of hepatitis C virus-directed translation by hammerhead ribozymes in vitro. Hepatology 22 (4 Part 2), 330A.

    Google Scholar 

  224. Carreno, V., and Quiroga, J. A. (1996) New and forthcoming therapies for viral hepatitis. J Hepatol. 24 (Suppl. 2), 74–76.

    PubMed  CAS  Google Scholar 

  225. Monjardino, J. (1996) Replication of hepatitis delta virus. J. Virol. Hep. 3, 163–166.

    CAS  Google Scholar 

  226. Polish, L. B., Gallagher, M., Fields, H. A., and Hadler, S. C. (1993) Delta hepatitis: molecular biology and clinical and epidemiological features (review). Clin. Microbiol. Rev. 6 (3), 211–229.

    PubMed  CAS  Google Scholar 

  227. Moestrup, T., Hansson, B. G., Widell, A., and Nordenfelt, E. (1983) Clinical aspects of delta infection. Br. Med. J. Clin. Res. Ed. 286 (6359), 87–90.

    PubMed  CAS  Google Scholar 

  228. Caredda, F., Antinori, S., Re, T., Pastecchia, C., and Moroni, M. (1987) Course and prognosis of acute HDV hepatitis. Prog. Clin. Biol. Res. 234, 267–276.

    PubMed  CAS  Google Scholar 

  229. Rizzetto, M., Verme, G., Recchia, S., Bonino, F., Farci, P., Arico, S., Calzia, R., Picciotto, A., Colombo, M., and Popper, H. (1983) Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment. Ann. Int. Med. 98 (4), 437–441.

    PubMed  CAS  Google Scholar 

  230. Fattovich, G., Boscaro, S., Noventa, F., Pornaro, E., Stenico, D., Alberti, A., Ruol, A., and Realdi, G. (1987) Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B. J. Infect. Dis. 155 (5), 931–935.

    PubMed  CAS  Google Scholar 

  231. Sagnelli, E., Felaco, F. M., Filippini, P., Pasquale, G., Peinetti, P., Buonagurio, E., Aprea, L., Pulella, C., Piccinino, F., Giusti, G. (1989) Influence of HDV infection on clinical, biochemical and histological presentation of HBsAg positive chronic hepatitis. Liver 9 (4), 229–234.

    PubMed  CAS  Google Scholar 

  232. Farci, P., Mandas, A., Coiana, A., Lai, M. E., Desmet, V., Van Eyken, P., Gibo, Y., Caruso, L., Scaccabarozzi, S., Criscuolo, D., et al. (1994) Treatment of chronic hepatitis D with interferon alfa-2a. (See comments) N. Engl. J. Med. 330 (2), 88–94.

    PubMed  CAS  Google Scholar 

  233. Hadziyannis, S. J. (1991) Use of alpha-interferon in the treatment of chronic delta hepatitis. J. Hepatol. 13 (Suppl. 1), S21 - S26.

    PubMed  Google Scholar 

  234. Gaudin, J. L., Faure, P., Godinot, H., Gerard, F., and Trepo, C. (1995) The French experience of treatment of chronic type D hepatitis with a 12-month course of interferon alpha-2b. Results of a randomized controlled trial. Liver 15 (1), 45–52.

    PubMed  CAS  Google Scholar 

  235. Battegay, M., Simpson, L. H., Hoofnagle, J. H., Sallie, R., and Di Bisceglie, A. M. (1994) Elimination of hepatitis delta virus infection after loss of hepatitis B surface antigen in patients with chronic delta hepatitis. J. Med. Virol. 44 (4), 389–392.

    PubMed  CAS  Google Scholar 

  236. Madejon, A., Cotonat, T., Bartolome, J., Castillo, I., and Carreno, V. (1994) Treatment of chronic hepatitis D virus infection with low and high doses of interferon-alpha 2a: utility of polymerase chain reaction in monitoring antiviral response. Hepatology 19 (6), 1331–1336.

    PubMed  CAS  Google Scholar 

  237. Arrigoni, A., Ponzetto, A., Actis, G., and Bonino, F. (1983) Levamisole and chronic delta hepatitis (letter). Ann. Int. Med. 98 (6), 1024.

    PubMed  CAS  Google Scholar 

  238. Craxi, A., Di Marco, V., and Volpes, R. (1990) Treatment with interferon alpha-2b of chronic HDV hepatitis in children. J. Hepatol. 11, S175.

    Google Scholar 

  239. Berk, L., de Man, R. A., Housset, C., Berthelot, P., and Schalm, S. W. (1991) Alpha lymphoblastoid interferon and acyclovir for chronic hepatitis delta. Prog. Clin. Biol. Res. 364, 411–420.

    PubMed  CAS  Google Scholar 

  240. Rosina, E., Conoscitore, P., Giuliani, A., De Filippis, G., Smedile, A., Bauducci, M., Mangia, A., Borghesio, E., Martinotti, R., Bonino, F., Recchia, S., Piobbici, M., Bonino, F., Verme, G., Andriulli, A., and Rizzetto, M. (1994) Treatment of chronic hepatitis D with the thymosin derivative the Gamma-2, Results of a pilot study. Hepatology 20 (4 Part 2), 309.

    Google Scholar 

  241. Samuel, D., Zignego, A. L., Reynes, M., Feray, C., Arulnaden, J. L., David, M. R, Gigou, M., Bismuth, A., Mathieu, D., Gentilini, P., et al. (1995) Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis. Hepatology 21 (2), 333–339.

    PubMed  CAS  Google Scholar 

  242. Simons, J. N., Pilot-Matias, T. J., Leary, T. P. Dawson, G. J., Desai, S. M., Schlauder, G. G., Muerhoff, A. S., Erker, J. C., Buijk, S. L., Chalmers, M. L., Van Sant, C. L., and Mushahwar, I. K. (1995) Identification of two flavivirus-like genomes in the GB hepatitis agent. Proc. Natl. Acad. Sci. USA 92(8) 3401–3405.

    PubMed  CAS  Google Scholar 

  243. Karayannis, P., Petrovic, L. M., Fry, M., Moore, D., Enticott, M., McGarrdey, M. J., Scheuer, R. J., and Thomas, H. C. (1989) Studies of GB hepatitis agent in tamarins. Hepatology 9, 186–192.

    Google Scholar 

  244. Schlauder, G. G.. Dawson, G. J., Simons, J. N., Pilot-Matias, T. J., Gutierrez, R. A., Heynen, C. A., Knigge, M. F., Kurpiewski, G. S., Buijk, S. L., Leary, T. P., Muerhoff, A. S., Desai, S. M., and Mushahwar, I. K. (1995) Molecular and serologic analysis in the transmission of the GB hepatitis agents. J. Med. Virol. 46 (1), 81–90.

    CAS  Google Scholar 

  245. Simons, J. N., Leary, T. P., Dawson, G. J., Pilot-Matias, T. J., Muerhoff, A. S., Schlauder, G. G., Desai, S. M., and Mushahwar, I. K. (1995) Isolation of novel virus-like sequences associated with human hepatitis. Nature Med. 1 (6), 564–569.

    PubMed  CAS  Google Scholar 

  246. Linnen, J., Wages, J., Jr., Zhang Keck, Z. Y., Fry, K. E., Krawczynski, K. Z., Alter, H., Koonin, E., Gallagher, M., Alter, M., Hadziyannis, S., Karayiannis, R, Fung, K., Nakatsuji, Y., Shih, J. W. K., Young, L., Piatak, M., Jr., Hoover, C., Fernandez, J., Chen, S., Zou, J. C., Morris, T., Hyams, K. C., Ismays, S., Lifson, J. D., Hess, G., Foung, K. H., Thomas, H., Bradley, D., Margolis, H., and Kim, J. P. (1996) Molecular cloning and disease association of hepatitis G virus: A transfusion-transmissible agent. Science 271 (5248), 505–508.

    PubMed  CAS  Google Scholar 

  247. Karayiannis, R, Hadziyannis, S. J., Kim, J., Pickering, J. M., Piatak, M., Hess, G., Yun, A., McGarvey, M. J., Wages, J., and Thomas, H. C. (1997) Hepatitis G virus infection: clinical characteristics and response to interferon. J. Viral Hep. 4, 37–44.

    CAS  Google Scholar 

Download references

Authors
  1. Christopher O’Brien
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dilip Moonka
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medical Microbiology and Immunology, University of South Florida College of Medicine, Tampa, FL, USA

    Steven Specter

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Science+Business Media New York

About this chapter

Cite this chapter

O’Brien, C., Moonka, D. (1999). Antiviral Chemotherapy for Viral Hepatitis. In: Specter, S. (eds) Viral Hepatitis. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-702-4_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-702-4_9

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-033-5

  • Online ISBN: 978-1-59259-702-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation